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Case presentation
A 33-year-old man was examined because he formed recurrent renal
calculi. At age 22, he had been hospitalized and had undergone
ureterolithotomy for a right-sided calculus composed of calcium oxalate
monohydrate and uric acid. During the ensuing Ii years, he passed 12
new stones, for which he was hospitalized eight more times, underwent
five cystoscopic procedures for stone removal, and had two more
ureterolithotomies, one on each side. His most recent x-ray films
disclosed three renal stones, of which two were on the left. Of the nine
that had been passed or removed, four were mixtures of calcium oxalate
and uric acid, three were pure calcium oxalate, and two were pure uric
acid. The remainder of his medical history was negative. His diet was
unremarkable except for a daily one-pound total intake of meat, fish,
and poultry.
Physical examination was within normal limits; the patient weighed
82.3 kg. Blood concentrations of calcium, uric acid, and creatinine were
normal. Three 24-hr urine samples were collected on an outpatient basis
while he followed his regular diet (Table 1). Urine calcium excretion
exceeded the normal upper limit of 300 mg/day for men, and uric acid
excretion exceeded the normal upper limit of 800 mg/24 hr. Urine
concentration of undissociated uric acid was uniformly above the
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solubility limit in urine, which is 96 2 mg/liter. His urine was
supersaturated 3.65- to 4.71-fold above the solubility product. The
degree of supersaturation with respect to calcium oxalate monohydrate
was determined by incubating an aliquot of each urine sample for 48 hr
at 37°C with 5 mg/mI of crystalline calcium oxalate monohydrate. The
ratio of the calcium oxalate concentration product before the incubation
to that after the incubation, termed the concentration product ratio
(CPR), provides a measure of supersaturation, the units of which are
multiples of the solubility product [II.
The patient was advised to eat a specified diet designed to provide 2
mg of calcium per kg body weight daily. The daily diet contained a total
of 9 ounces of meat, fish, and poultry; grains, fats, starches. and
vegetables made up the additional calories. His weight remained
unchanged at 82 kg. Studies of the urine on days 7, 8, and 9 of this diet
revealed that the calcium excretion exceeded calcium intake on each of
the 3 days (Table 2). Uric acid excretion fell to normal (<800 mg/24 hr),
and undissociated uric acid concentration declined to levels approach-
ing the solubility limit in urine.
Discussion
DR. FREDRIC L. COE (Director, Nephrology Program and
Professor of Medicine and Physiology, University of Chicago
Pritzker School of Medicine, Chicago, Illinois): Two different
crystals, uric acid and calcium oxalate, produced severe stone
disease in this patient. Some of his calculi were composed
exclusively of one of the crystals, whereas other stones were
composed of both. Most patients produce only calcium stones;
in our experience, only 11% of patients develop mixed types
(Table 3); rarer still are the few patients whose stones are pure
uric acid. One might think that each crystal forms because of a
distinctive urine chemistry disorder that may require treatment,
and as far as I can tell, this usually is the case.
Production of uric acid stones
Urine pH. Uric acid has two dissociable protons. The first
has a dissociation constant (pKa) of 5.35 in urine at 37°C [21.
Hydrogen urate, the product of uric acid dissociation, forms
salts in urine mainly with sodium, potassium, and ammonium.
Stones of sodium- or potassium-hydrogen urate are unknown,
and those of ammonium hydrogen urate are rare, but stones of
uric acid form easily. Undissociated uric acid itself is soluble in
human urine only up to concentrations of 96 2mg/liter at 37°C
[3]. The nomogram shown in Figure 1 can be used to estimate
uric acid supersaturation from 24-hr urine pH and the total uric
acid concentration (T), the quantity actually measured by the
clinical laboratory.
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Measurement
Day
1 2 3
Volume (ml/24 hr) 1560 1290 1475
Creatinine (mg/24 hr) 1675 1710 1689
Calcium (mg/24 hr) 398 347 455
Oxalic acid (mg124 hr) 36 41 38
Uric acid (mg124 hr) 982 1027 914
pH 5.72 5.64 5.81
Undissociated uric acid (mg/liter) 268 408 215
CPR (CaOx)b 4.71 3.65 4.26
Figure 1 also illustrates how urine pH predominates over
urine volume and total uric acid concentration in determining
undissociated uric acid concentration and, therefore, in predis-
posing to the formation of uric acid stones. When pH is below
5.5, urine volume must be nearly 2 liters to dissolve 600 mg of
uric acid, the amount excreted by a normal man [4]; whereas
when urine pH exceeds 6.0, even massive hyperuricosuria is
unlikely to cause supersaturation.
Clinical experience supports this reasoning (Table 3). In our
patients, urine pH was appreciably lower in uric acid stone
formers than it was in patients with other kinds of stones.
Moreover, low urine pH in uric acid stone formers was associ-
ated with higher values for undissociated uric acid supersatura-
tion. The urine of patients who produced only calcium stones
generally was not supersaturated with respect to uric acid,
whereas the urine of patients who formed both calcium oxalate
and uric acid stones was moderately but definitely supersaturat-
ed; this difference was attributable to differences in urine pH.
The patient presented today excreted urine that was excessive-
ly supersaturated with respect to uric acid (Table 1) because of
both low pH and hyperuricosuria.
Urine pH over the course of a typical day is abnormally low
in patients with gout [5] as it is in patients with a hereditary
predisposition to forming uric acid stones [61. The explanation
for aciduria in these conditions is unknown. Diseases of the
intestine and possibly of the kidney also can lower urine pH. In
small bowel disease or after ileostomy, bicarbonate is lost in the
stool, and renal acid excretion must rise to preserve systemic
acid balance. Diet also influences urine pH; for example, a high
intake of meat provides considerable methionine, the sulfhydryl
of which is oxidized to suifuric acid, a strong urinary acidifier
[7]. When today's patient ate less meat, he produced a less acid
urine that was also less supersaturated (Table 2).
Uric acid excretion. Hyperuricosuria itself can contribute to
uric acid stones by raising total uric acid concentration (Fig, 1).
Without some concomitant reduction of average urine pH,
however, hyperuricosuria rarely causes stones unless it is
massive. Tumor lysis, myeloproliferative disorders, and heredi-
tary conditions characterized by uric acid overproduction [8]
can raise urine uric acid excretion to 1000 or even 2000 mg
daily. Under these circumstances, the solubility limit for undis-
sociated uric acid can be exceeded even when urine pH is as
high as 6.0; acute and massive hyperuricosuria can cause
intratubular uric acid precipitation and acute renal failure [9].
Daily uric acid excretion is not routinely elevated in the usual
Day
Measurement 7 8 9
Volume (ml/24 hr) 1600 1590 1375
Creatinine (mg/24 hr) 1640 1678 1670
Calcium (mg/kg/24 hr) 3.72 3.64 3.80
Uric acid (mg/24 hr) 755 743 760
pH 5.95 6.12 6.0
Undissociated uric acid (mg/liter) 118 79.4 124
Studies were performed during the last 3 of 9 days that the patient
followed a low-calcium diet. Calcium intake on days 7, 8, and 9 was 2.1,
1.94, and 2.0 mg/kg124 hr, respectively.
patient with uric acid lithiasis; only 9 of our 22 patients were
hyperuricosuric (Table 3) [10]. However, modest hyperurico-
suria is more frequent in stone formers, even those who form
calcium oxalate stones, than in normal people [3,4, 11]. Dietary
purine excess from meat is probably responsible. The potential
for uric acid precipitation is compounded because urine pH is
slightly lower than normal in patients who eat large quantities of
meat [3, 12]. In today's patient, hyperuricosuria disappeared
when dietary meat intake was reduced (Table 2).
Production of calcium oxalate stones
Hypercalciuria in stone patients. The most dramatic differ-
ence between people who form calcium oxalate stones and
those who do not is that most stone formers excrete more
calcium in their urine [13], even though the serum calcium
concentrations are normal. The tendency towards normocalce-
mic hypercalciuria appears to be genetic [14]. Among people
who have never produced a stone, urine calcium excretion
spans a wide range, the upper end of which overlaps with the
range of values occurring in stone formers [15]; thus, stone
formers appear as though they had been selectively culled from
the upper tail of the normal distribution, over 50% having
calcium excretion rates that occur in less than 10% of normals.
Our cutoff for distinguishing between normal calcium excretion
and hypercalciuria, expressed as the amount of calcium excret-
ed in 24 hr, is 300 mg for men and 250 mg for women, or 4 mg/kg
in either sex [16].
Although convenient, this definition of hypercalciuria obvi-
ously is arbitrary. A more insightful approach is to determine,
for every level of calcium excretion, the likelihood of its
indicating a normal individual or a stone former. We studied
patients who were under treatment for recurrent stone disease.
Most remained stone-free; some went on to form more stones.
The technique of discriminant analysis allowed us to calculate
the relationship between a given calcium excretion rate and the
risk of forming a new stone. Using this technique, the 50%
probability point, which gives the dividing line between the two
groups, was found to be 2.4 mg/kg/24 hr, a value within the
usual range of normal [17]. The patient presented today excret-
ed between 4.2 and 5.54 mg/kg of calcium daily, far above the
threshold of nsk.
Hypercalciuria could increase the risk of calcium stone
formation by raising urine supersaturation with respect to
calcium oxalate. We [1] and others [18] have observed that
urine from patients with hypercalciuria was more highly super-
Table 1. Urine studies of the patient under discussiona Table 2. Urine studies of the patient under discussiona
Studies were performed with the patient following his regular diet.
b CPR refers to concentration product ratio; CaOx refers to calcium
oxalate monohydrate.
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Table 3. Selected laboratory measurements in patients with calcium, uric acid, or mixed stonesC
Types of stones
Calcium Mixed Uric acid(N = 821) (N = 109) (N = 22)
Serum determinations
Creatinine (mg/dl) .98 .01 1.02 .02b 1.06 .05
Uric acid (mg/dl) 5.70 .04 6.38 .14 5.96 .33
Calcium (mg/dl) 9.48 .01 9.55 .43 9.35 .06
Phosphorus (rngIdl) 3.17 .48 3.23 .62 3.25 .08
Urine determinations
Volume (liter) 1.59 .06 1.53 .05 1.51 .12
Calcium (mg/24 hr) 231 4 216 10 175 25
(mg/kg124 hr) 3.06 .05 2.62 .12" 2.12 .28C
Uric acid (mg124 hr) 700 40 665 20 669 40
pH 6.0 .4 5.7 .4 5.5 .4
Oxalate (mgIkgI24 hr) 39 16 38 1 36 3
All values are mean SEM. Reprinted from Kidney International (Vol. 22, 1982 with permission) [101.b Differs from calcium, P < .05.
Differs from mixed, P < .05.
"Differs from calcium, P < .01.
Differs from calcium, P < .001.
saturated with respect to calcium oxalate monohydrate than
was normal urine (Fig. 2). Today's patient exhibited supersatu-
ration between 3.65- and 4.71-fold, levels considerably above
usual normal limits.
Another line of evidence linking hypercalciuria and calcium
stone disease is that treatment of hypercalciuria with oral
thiazide diuretics greatly reduces the rate of new stone produc-
tion. Thiazides stimulate distal tubule calcium reabsorption [19]
and reliably lower urine calcium excretion in humans [20] and in
rats [21]. Chronic thiazide administration lowers calcium oxa-
late supersaturation in parallel with the decreasing urine calci-
um excretion (Fig. 3), and as a consequence might be expected
to prevent calcium stone formation. Our data [I] and those of
others [22] show a decrease in new stone production during
treatment with thiazides (Fig. 4).
Pathogenesis of hypercalciuria. Calcium stone disease ensu-
ing from hypercalciuria can be treated with thiazides, or a low-
calcium diet or agents such as sodium cellulose phosphate that
chelate dietary calcium and interfere with its absorption from
the intestinal lumen [23]. Probably any treatment that lowers
urine calcium excretion will reduce stone recurrence, but the
long-term systemic effects of a given treatment may depend on
the interaction between the influence of the treatment on
calcium metabolism and the underlying physiologic disorders
responsible for hypercalciuria. Genetic hypercalciuria is such a
complex amalgam of intestinal and renal disorders that its
pathophysiologic basis is far from obvious.
Virtually everyone with the syndrome absorbs dietary calci-
um at an accelerated rate (Table 4). Hyperabsorption would
tend to raise blood calcium concentration, increase the post-
prandial filtered load of calcium, and suppress secretion of
parathyroid hormone (PTH). The fall in PTH secretion in turn
would reduce renal tubular calcium reabsorption [24]. One
would predict from this sequence that the resulting hypercal-
ciuria would best be treated by the use of a low-calcium diet or
the administration of sodium cellulose phosphate. Even fasting
urine calcium levels are elevated in most patients, however
[25], and fasting values for fractional renal calcium reabsorption
are reduced [26, 27j; these findings suggest that the kidney's
ability to conserve calcium is less than normal.
When we challenged patients who have idiopathic hypercal-
ciuria by giving them a low-calcium diet for 9 days [28], urine
calcium losses were abnormally large (Fig. 5), and calcium
excretion frequently exceeded intake. Because these patients
also failed to conserve phosphate and magnesium as effectively
as did normals (Table 5), one can infer that tubular reabsorption
or bone metabolism of all three ions was abnormal. Only the
small fraction of patients who did conserve calcium normally
could be considered for therapy with a long-term low-calcium
diet or cellulose phosphate; most patients would be better
treated with thiazides. Today's patient excreted 3.6 to 3.8 mgI
kg/24 hr of calcium while ingesting 1.9 to 2.1 mg/kg/24 hr, and
he clearly is in the group that would not be best treated with
cellulose phosphate or a low-calcium diet, but may benefit from
thiazide.
Chronic thiazide therapy, however, is not without risk.
Zerwekh and Pak have found persistent calcium overabsorption
(estimated from unidirectional mucosal to serosal 47Ca move-
ment) during long-term thiazide therapy in a majority of patients
with hypercalciuria [29]. The only patients whose absorption
rates fell were those who had elevated serum PTH or urine
cAMP levels. These patients presumably had a predominant
renal tubular transport defect for calcium reabsorption that
provoked secondary hyperparathyroidism, increased serum
levels of 1 ,25(OH)2D3, and produced calcium overabsorption.
Because none of the patients we studied had elevated PTH (Fig.
5) or cAMP levels [28], we suspect that thiazides could cause
chronic calcium retention.
There is evidence that thiazide can induce calcium retention
in the rat. We increased intestinal calcium absorption by giving
rats subcutaneus l,25(OH)2D3 [21]. Urine calcium excretion
increased from an average value of 1.5 to 12.8 mg/24 hr;
virtually all of the increase was due to increased dietary calcium
absorption, as evidenced by the observation that a low-calcium
diet reduced urine calcium excretion to 0.8 mg/24 hr. When
chlorothiazide was given to rats receiving l,25(OH)2D3 and
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eating normal chow, mean urine calcium fell from 12.8 to 6.6
mg/day. We found no evidence from studies of everted gut sacs
that chiorothiazide caused a concomitant reduction in intestinal
calcium absorption in these animals, however. Colonic calcium
transport, measured in the Ussing chamber, also was unaltered
when chlorothiazide was added to the medium. One can infer
from this series of observations that approximately 6 mg/day of
calcium was being absorbed and not excreted. If these data can
be extrapolated to humans, and if studies of segmental transport
predict overall intestinal absorption, thiazides might cause
calcium retention in patients with nephrolithiasis.
Despite these experimental findings, the balance of evidence
favors thiazide therapy for idiopathic hypercalciuria. The alter-
native, treatment with a low-calcium diet, seemed to deplete
total-body calcium stores, at least over the short term, in our
studies [28]. Chronic calcium accumulation during thiazide
therapy has not been documented in humans with hypercal-
ciuria. If it does occur, it might not even be disadvantageous,
provided the calcium accumulates in bone. A key experiment
that has not yet been performed in patients with hypercalciuria
is administration of a low-calcum diet over many months, with
intermittent measurement of the precise levels of intake and
excretion to determine whether negative calcium balance per-
sists. Perhaps immediate losses are from unessential stores that
are readily mobilized, whereas structural bone mineral is better
protected. Another key experiment that should be done is
determination of the effects of thiazides on external calcium
balance in patients with genetic hypercalciuria.
Role of hyperoxaluria. Although not a substrate for mammal-
ian enzymes, oxalic acid is produced from glycolate. Also,
dietary oxalate is absorbed by the gut at a rate of approximately
2 to 6 mg/day in normal individuals [30]. The urine is the only
Idiopathic Hyper- Normal
hypercalciuria uricosuria Both Neither subjects
(42) (14) (14) (41) (28)
Fig. 2. Calcium oxalate concentration product ratio (CPR) in 24-hour
urine collections from III calcium stone formers and 28 normal
subjects. Each point represents a single urine sample. The number of
patients in each category is shown in parentheses. One normal subject
was studied twice and had urine CPR values of 3.2 and 5.2. The rest
each contributed one urine value to the figure. Forty patients elaborated
at least one urine sample with CPR above 3: 22 had hypercalciuria, 3
had hyperuricosuria, 9 had both, and 6 had neither. (From Ref. 1.)
vehicle for excretion, and urinary oxalate concentration nor-
mally varies between 100 and 400 M [I]. Urine calcium
concentration normally varies between 3.0 and 7.5 mM. Using
the extremes of both ranges to calculate chemical concentration
products yields values of 3 x l0— and 30 x l0— M2, respec-
tively. The equilibrium solubility product (Ksp) for calcium
oxalate monohydrate is only about 2.3 x l0— M2 [311. Thus,
normal levels of urinary calcium and oxalate could exceed the
Ksp by more than 100-fold [1].
The large driving force for crystal formation implied by this
calculation is offset by formation of complexes and by at least
one substance in urine that interferes with the growth of
calcium oxalate crystals. Were it not for these offsetting influ-
ences, even normal urine would produce crystal most of the
time. Calcium forms soluble salts in urine mainly with citrate
and phosphate. As a result, ionic calcium is reduced to only
about 50% of the total calcium concentration [32]. Oxalate
forms a sodium salt, which represents as much as 40% of the
total oxalate in urine, as well as some soluble calcium salts.
Therefore, ionic oxalate probably is reduced to about 40% of
the total. Because of these soluble complexes, the final product
of the urine calcium and oxalate ion activities is not more than
20% to 25% of the chemical concentration products [33]; still,
this value is far above the Ksp.
Despite the supersaturation, normal urine can inhibit crystal
development so effectively that calcium oxalate crystals are not
usually seen. This inhibitory power might reside in a specific
glycoprotein that has very unusual properties [31, 34, 35], The
protein weighs about 14,000 daltons. It is strongly acidic, in part
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Fig. 1. Nomogram showing undissociated uric acid concentration at
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Fig. 3. Effects of thiazide treatment on 24 patients whose pretreatment
24-hour urine concentration product ratio (CPR) exceeded 3. Four
patients (open circles) were not hypercalciuric; the remainder (closed
circles) were. The average pretreatment values of concentration prod-
uct ratio (lower panel) and concentration product (upper panel) are
shown as well as each set of values obtained during treatment. Thiazide
treatment lowered concentration product ratios progressively in every
patient; urine concentration product also tended to decline, especially
when it had been very elevated before treatment. (From Ref. 1.)
because aspartic and glutamic acids predominate over lysine
and arginine and probably because it contains y-carboxygluta-
mic acid as well. The protein seems to act as an inhibitor by
adsorbing to crystal surfaces [34], but the details of this action
are unknown.
Hyperoxaluria, like hypercalciuria, raises the urine ion activi-
ty product and upsets the normal balance between supersatura-
tion and inhibition, so crystals are more likely to form. An
increase in oxalate concentration increases supersaturation
even more than an equivalent increase in calcium concentration
does [361, perhaps because oxalate forms fewer soluble salts in
urine; any increase in oxalate chemical concentration therefore
is more directly translated into increased supersaturation.
The main reasons for hyperoxaluria are dietary excess and
intestinal disease. Hereditary disorders of metabolism rarely
cause primary oxalate overproduction; dietary excess usually
arises from ingestion of foods that contain more than 0.1%
oxalate by weight. For an intestinal disease to cause hyperoxa-
luria, it must result in small bowel malabsorption and it must
occur in the presence of a functioning colon. Products of
digestion and secretion, such as ricinoleic acid or taurocholic
acid, usually are absorbed by the jejunum and ileum and do not
reach the colon [37]. heal disease or resection, however, may
permit such materials to reach the colon, where they can
increase permeability to oxalate [38]. Lumen oxalate concentra-
tions probably are in the millimolar range, whereas blood levels
are about 2 to 4 M [39], so there normally exists a considerable
driving force for absorption that is enhanced when permeability
increases. The patient under discussion today was not
hyperoxaluric.
Role of defective inhibitors. It seems reasonable to speculate
that some people, perhaps because of random genetic variabili-
ty, produce an abnormally low quantity of inhibitors, or an
inhibitor of abnormally low activity, and form calcium stones
on this basis. Patients with calcium oxalate stones have been
found to have considerably lower values than normal even
though their urine was also more supersaturated with respect to
that crystal [40]. Quite possibly, reduced inhibitory power leads
to stone formation, but this never will be proven until the
inhibitory substance is measured directly; such measurements
are not yet possible. One observation, however, might link
altered inhibition to stone formation. Young children produce a
protein that has stronger inhibitory properties than that of
adults, and children—even those with hypercalciuria—rarely
produce calcium oxalate stones [41]. The peak age of onset for
stone production is 18 to 20 years, just after growth ceases [42].
No measurements of inhibitory activity were made for the
patient under discussion, so the role of reduced inhibition in his
disease is unknown.
Role of heterogeneous nuclei. Hypercalciuria and hyperoxa-
luria raise urine supersaturation and produce a milieu condu-
cive to crystallization. But the zone of metastability for calcium
oxalate monohydrate (which extends from the Ksp to the
activity product that produces an apparent solid phase) encom-
passes an 8-fold range in artificial buffers and a 12-fold range in
urine. This wide range reflects urine inhibition of the growth of
crystal nuclei [18]. The metastable zone exists because mole-
cules in solution tend to distribute themselves randomly, under
the influence of thermal motion, rather than aggregate in
crystals. The only reason that crystals do form is that, by
chance alone, atoms inevitably coalesce into momentary, tran-
sient clusters; when they approach each other closely, attrac-
tive forces between calcium and oxalate (mainly hydrogen
bonding) counteract the tendency each atom has to fly away
again. The total binding force increases with the size of the
cluster, so the largest ones tend to persist and, by holding on to
such new atoms as come by, grow into regular crystals.
Supersaturation is a measure of atomic crowding in a solution,
metastability a reflection of the balance between attractive
forces and the escaping tendency of atoms in an aggregate of a
given size, weighted by the probability of having aggregates of
that size.
Now imagine that, into a metastably supersaturated solution
0
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with an activity product exceeding Ksp by only two-fold, I
should add a preformed solid phase of calcium oxalate, already
having atoms with considerable internal attractive forces. This
solid surface will attract new atoms and grow, because the
density of mobile ions in solution will cause more atoms to
bombard the surface than can disengage themselves and es-
cape; the fact of crystal growth in a solution that cannot create a
new solid phase do novo is the very definition of solution
metastability. Stated more technically, addition of a solid phase
abridges the thermodynamically costly process of nucleation
and permits the formation of more stable aggregates.
Because new crystal nuclei are very small, the urine that
flows continuously from tubule orifices into the bladder sweeps
away all but those large enough to lodge in some crevice or
occlude the lumen of a terminal collecting duct. Clinical nephro-
lithiasis depends upon collecting nuclei into large crystal aggre-
gates. Newly formed microcrystallites can adhere to the sur-
faces of preformed crystals. If the conditions are right and if the
preformed surface is much larger than the microcrystallites, the
surface can serve as an organizing template that holds many
microcrystallites together, thus producing sizable aggregates.
The idea that added crystals of calcium oxalate can promote
calcium oxalate nucleation and foster development of even
larger crystals is, of course, a circular notion; there are no
preformed calcium oxalate crystals in the kidneys or urine
unless supersaturation is extreme enough to produce them—
and they would not be large unless they grew that way. But
evidence does indicate that the surface of an entirely different
crystal, uric acid, can substitute for the surface of calcium
oxalate, permit crystal formation at low degrees of calcium
oxalate supersaturation, and serve as a template for microcrys-
tallite organization [43, 44].
The fate of uric acid crystals bathed in a solution containing
uric acid, calcium, and oxalate is influenced by the solution's
concentration of undissociated uric acid ([HU]). If [HU] is
below 96 mg/liter at 37°C, the uric acid crystals dissolve. If
[HU] exceeds 96 mg/liter, uric acid competes with calcium and
oxalate for the crystal surface, and competition is governed by
their relative supersaturations. Conditions best suited to the
formation of calcium oxalate surface are found in a solution
supersaturated slightly with HU and strongly with respect to
calcium oxalate. Very high [HU] causes growth of uric acid
crystals alone. A high degree of supersaturation with respect to
both favors mixed crystals of uric acid and calcium oxalate, like
those in today's patient.
Among calcium oxalate stone formers, hyperuricosuria ap-
pears almost as commonly as does hypercalciuria [45—47] and
seems mainly due to a high intake of meat, fish, and poultry.
Indeed, this was the cause of the hyperuricosuria in the patient
described today. Patients with hyperuricosuria and calcium
oxalate stones excrete urine that is more supersaturated with
respect to uric acid than normal urine or urine of patients with
hypercalciuria alone (Table 6), partly because their high meat
intake lowers urine pH. When we reduced uric acid excretion
with allopurinol, we found [45] that production of new calcium
oxalate stones decreased greatly (Fig. 6); this observation has
been confirmed by others [48].
In hyperuricosuric calcium oxalate nephrolithiasis, we have a
Fig. 4. Calcium stone formation before and
during treatment of hypercalciuria with
thiazide. Each patient is shOwn as a horizontal
line; new stones are designated by closed
symbols; multiple stones occurring in cluster
are shown as open symbols. (From Ref. 16.) 0
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Table 4. Intestinal calcium absorption in normal subjects and in patients with idiopathic hypercalciuria*
Reference Method
Calcium intake
(mg/day)
Percentage of dietary calcium absorbed
Normals Patients
Cannigia et al 1964 Fecal 45Ca Free** — 22.0 (l)***
Birge et al 1969 47Ca po/iv 800 52.2 13.2 (6) 58.5 8.6 (4)
Wills et al 1970 47Ca po/iv 400 49.0 10.0 (4) 76.0 17.0 (5)
Pak et al 1972 Fecal 47Ca 400 45.6 9.0 (29) 69.7 7.0 (9)
58.1 13.0 (Il)t
Pak et al 1974 Fecal 47Ca 400 50.0 7.0 (20) 71.7 7.0 (22)
50.0 17.0 (2)
Ehrig et al 1974
Kaplan et al 1977
47Ca145Ca
po/iv
Fecal 47Ca
462—952
400
—
48.0 8.0 (II)
47.8 11.0 (22)tt
37.6 11.0 (22)H
80.0 9.0 (2ll)*
73.0 7.0 (3)
Shen et al 1977 47CaJ45Ca Free** 27.0 9.0 (14) 40.0 9.0 (15)
Barilla et al 1978
po/iv
Fecal 47Ca 400 None studied 69.5 6.4 (10)
70.1 10.4 (8)
Zerwekh et al 1980 Fecal 47Ca 400 None studied 69.0 7.0 (ll)
68.0 9.0 (l0)
* Values are mean SD. Reprinted from Ref. 46.
** Usual diet was not measured.
*** Numbers in parentheses indicate patients studied.
t Eleven patients listed as having normocalcemic primary hyperparathyroidism may be considered hypercalciuric.
"Absorptive" idiopathic hypercalciuria.
§ "Renal" idiopathic hypercalciuria.
tt Prior to therapy.
H 3—16 months after hydrochlorothiazide therapy began.
clear instance of how inheritance and environment can interact
to produce disease. Our hypothesis is that hypercalciuria is not
a disease but a reflection of a genetic variability that causes a
high traffic of calcium through the bodies of many people; we
have no reason to believe that the genetically determined range
of urine calcium excretion has varied much over centuries. The
level of urinary uric acid, however, is mainly determined by
culture, which reflects one's ability to afford the cost of a high-
meat diet. Moreover, the level can vary greatly. In the United
States, for example, the daily intake of meat products increased
from 7 to II ounces per person between 1905 and 1975 [49].
Duing the same period, widespread use of refrigeration made
fresh fruits and vegetables available year round and resulted in
a steadier intake of oxalate. For those people who inherit a
tendency toward hypercalciuria, an increased oxalate intake
results in higher urine supersaturation, and a higher meat intake
causes increased uric acid excretion and lower urine pH.
Supersaturation is the tinder; uric acid crystals are the match.
Today's patient, whose hyperuricosuria was clearly of dietary
origin, illustrates this phenomenon very well.
Mixed calcium oxalate and uric acid stones
The patient under discussion produced two types of crystals
at least partly because he produced urine that was abnormally
supersaturated with respect to both uric acid and calcium
oxalate. Increased uric acid, moreover, could well have fos-
tered the formation of calcium oxalate stones. This patient is
representative of a large group of patients we have studied (Fig.
7) [10]. Patients like this one have doubly supersaturated urine;
those with either calcium oxalate or uric acid stones show an
imbalance in supersaturation that favors one crystal over the
other. Balanced supersaturation must favor mixed stones given
that crystals of uric acid and calcium oxalate share an identical
pattern of surface charges; because chance variations of super-
saturation dictate which phase grows, random layers form, first
one crystal and then the other.
In terms of stone production rate and morbidity, calcium
oxalate stone formers and uric acid stone formers are at the
extremes of a range nearly bisected by patients who form mixed
stones (Table 7) [10]. Why uric acid stones recur more frequent-
ly is unknown, but it could be because urine has little effect on
uric acid solubility or crystal growth.
Both abnormalities of urine chemistry should be corrected,
because either can give rise to stones. In most instances,
increased calcium oxalate supersaturation results from genetic
hypercalciuria (which is treatable with thiazides), primary
hyperparathyroidism, dietary hyperoxaluria, or low fluid in-
take. Elevated uric acid supersaturation always reflects low
urine pH, elevated total uric acid concentration, or both. Dual
treatment with thiazides and allopurinol tends to protect against
new stones (Table 7), as one would expect. The patient present-
ed today had hypercalciuria, which might not have responded
well to a low-calcium diet, but it should have responded well to
thiazide. His hyperuricosuria, low urine pH, and increased
urine concentration of undissociated uric acid responded well to
reduced purine intake, which can be an ideal treatment. If he
had not agreed to alter his diet, allopurinol therapy would have
been a rational alternative.
Questions and answers
DR. JEROME P. KASSIRER: Many physicians, of course, do
not have ready access to a laboratory sophisticated enough to
o
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Fig. 5. Calcium intake and excretion (A) and serum PTH and I,25(OH)2D3 (B) values in patients and normal subjects. Urine calcium excretion
(UCa) and intake (Cal) were measured during a period of low-calcium diet. Serum values obtained during both low-calcium diet (I) and free-choice
diet (0) are shown. Normal subjects and patients are shown in order of ascending mean calcium excretion. Patients 24 and 26 were mothers of pa-
tients 16 and 36, respectively. Mean calcium intakes of normal subjects (2.29 0.15 SEM) and patients (2.31 0.05) did not differ significantly.
Mean excretion rates during low-calcium diet for normals (1.18 0.11) and patients (2.87 0.11), and values of intake minus excretion (Cal —CaE)
for normals (1.14 0.12) and patients (—0.58 0.11)differed significantly from each other (P < 0.001 for both). Similarly, calcium excretion in nor-
mal subjects (1.78 0.16) and patients (4.38 0.15) during free-choice diet (not shown) differed from each other (P < 0.001)and from values during
low-calcium diet (P < .01 for both normal subjects and patients). (From Ref. 28.)
examine renal stones in such detail. Is it possible for us to
adequately evaluate patients who form multiple stones if we use
fewer than the full array of elegant studies you described? For
example, should we routinely measure parathyroid hormone?
Should we always do the CPR test? Or would the simple
measurement of 24-hr urine calcium and uric acid with the
patient on a normal diet be sufficient?
DR. C0E: Ideally, every patient with a calcium oxalate kidney
stone should have the 24-hr urine calcium and serum calcium
concentrations measured as accurately as possible. Uric acid
excretion also should be measured, but one must remember that
erroneous values can obtain if techniques designed to measure
serum rather than urine uric acid are used. A specialized
laboratory such as ours probably is best reserved for the study
of patients in whom a clear diagnosis of hypercalcemia, hyper-
calciuria, or hyperuricosuria cannot be made routinely. Urine
oxalate is difficult to measure at the moment, and I would not
advise that routine oxalate screening be done.
DR. MARK SHIELDS (Attending Physician, Michael Reese
Hospital): Most of the data you have presented concern pa-
tients with multiple, recurrent stones. A common problem
facing the clinician is how aggressive one should be in evaluat-
ing and treating patients who have had only a single stone. What
do you recommend under such circumstances?
DR. C0E: We have observed that patients with a single stone
also have metabolic disorders with the same frequency as do
patients with multiple stones [50]. During treatment, these
patients suffer a relapse of stone disease at roughly the same
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Table 5. Phosphorus and magnesium values in norm al subjects and in patients with idiopathic hypercalciuria
Measurement
Normal subjects Patients
Low-calcium
diet
Free-choice
diet
Low-calcium
diet
Free-choice
diet
Serum phosphorust'
Phosphorus intake
Phosphorus excretionc
Cp/Ccr(%)
Serum magnesium'
Magnesium intake
Magnesium excretion
3.41 0.68
10.9 0.60
8.94 0.41d
11 1
1.98 0.02
2.32 0.65
1.11 0.44
3.41 0.60
—
11.5 0.6
14 1
1.93 0.02
—
1.3 0.1
3.22 0.06
10.6 0.30
11.6 4i
17 I'
1.97 0.02
2.25 0.06
1.32 O.04eh
3.22 0.06
—
13.9 0.5t'
19 I
2.01 0.01
—
1.57 0.65
Reprinted from Ref. 28.
b Serum values are measured in mg/dl.
Intake and excretion are measured in mglkg/24 hours.
' Differs from free diet; P < 0.02.
Differs from free diet; P < 0.00 1.
Cp/Ccr refers to phosphate clearance/creatinine clearance.
g Differs from normal, same diet; P < 0.05.
Differs from normal, same diet; P < 0.01.
Differs from normal, same diet; P < 0.001.
Table 6. Summary of urinary uric acid saturation measurements
24-hour urine values
Metabolic group
Normal
(N = 20)
1H
(N = 24)
HU
(N = 12)
Both
(N = 14)
Neither
(N = 17)
No. of samples
Total uric acid, mg/liter
Urine volume, ml
Urine pH
Undissociated uric acid", mg/liter
CPR, monosodium urate
Initial [Na) . [urate]c, M2 X i05
Final [Na] . Lurateld, Al2 X 1O
Sodium concentration, mEqlliter
24
503 32
1268 65
6.22
57 8i
2.8 0.3
37 4
13.2 0.7
131 8i
69
421 23
1717 133hJ
5.92
84 II
2.2 0.2
27 3
11.0 0.5
118 7
36
575 28
1501 79
5.62s
155 21"
2.7 0.2
35 4
12.0 0.6
130 7
42
616 27
1397 70
574a
150 16
3.1 0.2
42 3i
12.9 0.5
149 7'
51
462 32
1387 90
5.67"
128 18s
2.2 0.2
29 3
13.2 1.0
132 7
All values, except for the numbers of samples and the numbers of people in each metabolic group (in parentheses), are the means SEM.
Abbreviations used are: IH, idiopathic hypercalciuria; HU, hyperuricosuria; CPR, concentration product ratio; [Na], sodium concentration (mEq/
liter); [urate], urate concentration (mmoles/liter). Reprinted from Kidney International (Vol. 17, 1980 with permission) [3].
The mean equilibrium value, determined in 26 urine samples of pH below 5.6, after 48 hours of incubation with crystals of uric acid, was 90 5
mg/liter.
Before incubation with crystals of sodium hydrogen urate.
d After 48 hours of incubation with crystals of sodium hyrodgen urate.
Based upon the study of the 16 of the 20 normal subjects who had CPR measurements.
P < 0.05, compared with control.
P < 0.02, compared with control.
P < 0.01, compared with control.
P < 0.001, compared with control.
P < 0.05, men vs. women.
P < 0.02, men vs. women.
rate. There are no satisfactory prospective studies of the natural
history of untreated solitary stone disease, but two retrospec-
tive studies that I have reviewed elsewhere suggest that most of
these patients ultimately become recurrent stone formers [47].
In other words, the solitary stone former usually is someone
destined to be a recurrent stone former.
DR. JORDAN J. COHEN: Is there a role for measuring plasma
ionized calcium? Can it help distinguish intestinal versus renal
hypercalciuria? And is it useful in identifying patients with mild
hyperparathyroidism in whom serum calcium levels might not
be clearly elevated?
DR. C0E: Ionized calcium measurements are neither intrinsi-
cally more accurate nor more discriminating than are measure-
ments of total serum calcium, as far as I know. In our study of
hyperparathyroid stone disease, we observed that a large
fraction of the patients referred to us had serum calcium levels
that were elevated by our standards, but only to the range of
10.1 to 10.5 mgldl [51]. Such patients would be classified as
"normocalcemic" in a laboratory with a wider range of normal.
I suspect that as clinical laboratories become more sophisticat-
ed in measuring serum calcium and as their ranges of normal
shrink, diagnosing primary hyperparathyroidism will be no
easier using ionized calcium, especally if patients with serum
calcium levels above 10.1 mgldl have repeated serum calcium
measurements.
DR. KASSIRER: Most people find it difficult to change their
Fig. 6. Calcium stone formation before and
during treatment of hyperuricosuria with
allopurinol. Each patient is shown as a
horizontal line; new stones are represented as
closed symbols; and multiple stones in
clusters are illustrated as open symbols.
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dietary habits, and they often choose not to do so. In patients
who form uric acid stones, an alternative to the lifelong
ingestion of a restricted protein intake is allopurinol therapy. If
patients were given the choice and were told precisely what the
risks of allopurinol were—and I think the hazards are relatively
small—these patients might choose to take the drug rather than
follow a diet. Shouldn't the choice of treatment be made by the
patient?
DR. C0E: If a patient won't accept the recommendation to
reduce meat, fish, and poultry intake, treatment with allopuri-
nol is the only rational alternative. I agree with you that the
risks of allopurinol are few and that patients who reject dietary
protein restriction should have the drug.
DR. KASSIRER: Does one really need to do any fancy urinary
studies in patients who form uric acid stones or calcium oxalate
stones? If we use a few screening tests to rule out serious
diseases and we also have the information from the stone
analysis, why not simply treat all the patients?
DR. C0E: The notion of treating all patients who form calcium
oxalate stones and studying only those who relapse during
treatment is an intriguing and, I think, a legitimate topic for
study. One could compare the results of such a strategy with the
conventional approach, but I would raise certain cautions.
Specific treatment is necessary in patients with hypercalcemia,
intestinal disease and oxaluria, renal tubular acidosis, and also
in patients who may harbor underlying systemic diseases with
disordered divalent mineral metabolism, such as hyperthyroid-
ism, rapidly progressive bone disease, Cushing's syndrome, or
sarcoidosis. Even if that is done and one is left with normocal-
cemia in otherwise healthy people who form calcium stones,
one still must decide whether to treat these people with thiazide
alone, thiazide and allopurinol, or thiazide and a low-purine
diet. Should one routinely lower dietary oxalate intake, even
though most patients are not hyperoxaluric? Overall, there are
uncertainties about treating without pretesting, and I submit
that the matter requires a prospective study.
DR. DAVID BUSHINSKY (Staff Nephrologist, Michael Reese
Hospital): In your balance studies you showed that at least one-
half of your patients with idiopathic hypercalciuria were in
negative calcium balance. If negative calcium balance persisted
daily over long periods, one might expect to see the develop-
ment of either osteoporosis or other metabolic bone disease. Do
patients with idiopathic hypercalciuria have an abnormally high
frequency of bone disease?
Calcium Mixed Uric acid
stones stones stones
N=821 N=109 N = 22
Fig. 7. Calcium oxalate and undissociated uric acid supersaturation in
stone-forming patients. Values above 1 for CPR (open bars) indicate
supersaturation. The solubility of undissociated uric acid (hatched bars)
in urine is 96 3 mg/liter; hence, relative supersaturation can be
calculated by dividing the values shown by 96. The CPR values were
obtained from 431 patients with calcium oxalate, 56 with mixed calcium
oxalate and uric acid, and 9 with pure uric acid stones; corresponding
numbers of patients providing values for undissociated uric acid were
811, 106, and 22. All values are mean SEM. Asterisks indicate that
the values differ from the respective levels in both mixed and uric acid
stone groups; P < .001. (Reprinted from Kidney International. (Vol. 22,
1982 with permission) [101.
DR. C0E: The negative calcium balance we observed was
manifested while the patients followed a diet extremely low in
calcium. Normal diets provide much more calcium, and nega-
tive calcium balance would not be expected.
DR. IRVING ZITMAN (Attending Physician, Michael Reese
Hospital): Is it important that we know how much water a
person with nephrolithiasis takes in?
DR. C0E: The 24-hr urine volume gives an excellent estimate
of water intake in relation to need. It is best that patients with
recurrent stone disease have a urine volume of at least 1500 ml/
day, and fluid intake should be adjusted appropriately.
DR. COHEN: How effective is thiazide therapy in the normo-
calciuric patient who forms calcium stones?
--
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Table 7. Clinical characteristics of patients with calcium, uric acid, or
mixed stonesa
Type of stone
Calcium Mixed Uric acid
Number of patients (males, females) 821, 197 109, 20 22, 4
Number with multiple stones 646 101 17
Age at first stone (year) 36 36 46
Pretreatment interval (pt year)b 5770 1072 88.2
Total recurrent stones 4946 1254 224
Recurrent stones/lOO pt years 85.7 117b 254
Hospitalizations/100 pt yrs 25.4 29.9b 31.7"
Cystoscopies/100 Pt yrs 13.8 21.8" 19.2"
Infections/lOO pt yrs 6.9 44b 2.3b
Surgeries/l00 pt yrs 7.8 55b 10.2"'
Treatment interval (pt yrs) 313 71
Total new stones 48 12
Patients with new stones 13 2
Predicted stones 366 180
% of patients stone free 88 91
a Reprinted from Kidney International (Vol. 22, 1982 with permis-
sion) [101.
b Total years between onset of first stone and institution of treatment
for each patient multiplied by the total number of patients forming
calcium oxalate, mixed calcium oxalate and uric acid, or pure uric acid
stones.
Differs from calcium, P < .001.
d Differs from mixed, P < .001.
Percentage of patients stone free for this group [4, 11, 171 has
averaged 89%.
DR. C0E: Our studies [46] and studies by Pak et al [52] and
Maschio and colleagues [53] have included some patients who
do not have frank hypercalciuria. Treatment results seem
indistinguishable from those observed in patients with hypercal-
ciuria. This finding is not surprising given that thiazides lower
urine calcium excretion even in normocalciuric people, and that
risk of stone formation is increased by levels of calcium
excretion within the normal range.
DR. COHEN: Does the effect of thiazide vary in relationship to
the amount of salt in the diet? Does a high-salt diet offset the
hypocalciuric effect?
DR. C0E: High salt intake can increase urine calcium during
thiazide treatment [46]. Whether salt loading causes relapse of
stone formation despite adequate thiazide therapy is unknown.
DR. GERALD SOBEL (Attending Physician, Michael Reese
Hospital): Are there circumstances in which manipulating di-
etary oxalate might be helpful?
DR. C0E: Some patients have elevated urine levels of oxalate,
that is, above 45 to 50 mg124 hr, and these individuals have no
recognized underlying disease that could predispose to oxa-
luria. In many such patients, dietary oxalate intake is elevated,
and restriction of high-oxalate foods is appropriate.
DR. STEPHEN MICHEL (Renal Fellow, Michael Reese Hospi-
tal): Do we know what effect thiazide has on intestinal calcium
transport?
DR. COE: The only direct data I know of concerning the effect
of thiazide on intestinal calcium transport per se have been
published by Favus et al [21]. Thiazide does not appear to
reduce radiolabeled calcium accumulation by everted gut sacs
made from rat intestine, and thiazide does not alter either
mucosal-to-serosal or serosal-to-mucosal calcium flux in colon
mounted in Ussing chambers. The actual effect of thiazide on
overall human intestinal calcium absorption is unknown. To
find out what the effects are, one would have to measure total
calcium absorption before and after giving the drug.
DR. KASSIRER: Is anything known about the molecular mech-
anism of thiazide's effect on calcium transport in the renal
tubule?
DR. C0E: The effect of thiazide on tubular calcium transport
has been documented by microperfusion experiments [19], but
nothing is known about the molecular mechanism of this
transport effect.
DR. CRAIG LANGMAN (Pediatric Nephrolo gist, Michael
Reese Hospital): Kidney stones are very rare in children. Why
does this disease primarily affect adults?
DR. C0E: Renal calculi are indeed much less common in
children than in adults. On the other hand, idiopathic hypercal-
ciuria appears to be genetic and is as common in the pediatric
population as in the adult population [41]. It is not clear why
children are spared from developing stones.
DR. COHEN: In your opinion, are there any stone formers in
whom crystalloid excretion is normal and in whom the only
defect is an abnormal or absent urinary inhibitor?
DR. C0E: We have found that the urine of patients who have
renal calculi reduces crystal growth inhibition as compared to
urine from normal people [9]. Some stone-forming patients with
little crystal growth-inhibiting effect in their urine are not
hypercalciuric and do not appear to have excessive supersatu-
ration [40]. Perhaps such patients illustrate an abnormal urinary
inhibitor leading to stones, Demonstration of this possibility
would require specific measurements of inhibitors by immuno-
assay or isolation of an abnormal inhibitor.
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